Quick Summary — MEDP scores higher on quality with 10.0/10 vs NEO's 6.8/10. MEDP trades at $445.59 while NEO trades at $10.12. Both analyzed daily using SEC EDGAR data across 13 institutional models.
MEDP scores higher with a 10.0/10 quality rating vs NEO's 6.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
At $445.59, MEDP trades +12.6% above its Bayesian DCF fair value of $389.44, while NEO at $10.12 trades +95.9% above its estimate of $0.41. NEO shows a wider gap between price and intrinsic value.
MEDP earns a Quality of Company score of 10.0/10 compared to NEO's 6.8/10. This is a significant quality gap — the higher-scoring company demonstrates materially stronger fundamentals across profitability, growth consistency, and balance sheet health. The QOC score synthesizes 32 signals spanning profitability margins, revenue growth, free cash flow, capital allocation, and leverage.
MEDP carries a SAFE value trap risk (6/100) while NEO shows LOW risk (25/100). Both companies show manageable value trap risk, suggesting their current valuations are not artificially depressed by fundamental deterioration.
Both MEDP and NEO operate in Diagnostics & Research, which has 48 stocks tracked by CirclFi. Same-industry comparisons provide the most direct insight into relative valuation since both companies face similar regulatory environments, market dynamics, and competitive pressures. Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN), and ensemble methods (CUCE).
11 hidden models compare MEDP vs NEO differently — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more. Some may disagree with the 2 you see above.
Bloomberg Terminal: ~$2,000/mo · FactSet: ~$1,000/mo · CirclFi: $0.90/day
See All 13 Models — $0.90/dayWe don’t predict prices. We show you what 13 independent mathematical frameworks say a stock is worth — and let you decide.